Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019163 (
hepatitis B
)
38,309
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Viral hepatitis features with an incidence of 500 Mio infected individuals worldwide. Chronification of the infection as seen in hepatitis C, B, and D may lead to liver cirrhosis and its associated complications in later stages of the disease. Especially the chronification of acute hepatitis C is observed in a majority of cases (50-80%). Chronic Hepatitis C (cHC) should be treated in generally when elevated serum concentrations of liver enzymes are found or symptoms of disease occur. Treatment goals are viral elimination, improve in histology, prevention of
HCC
, and a better quality of life for the patients. As HCV and HIV share the same transmission routes, a relatively high rate of HCV-HIV co-infection is observed. Co-infection is characterized by a more progressive natural course of HCV-infection, leading to an increased mortality due to liver failure in the afflicted patients. The development of treatment options for anti-HCV-specific therapy in dually infected patients is urgently needed. The European Conference on Infectious Diseases and Tropical Medicine, EuCID 2001, which took place in May 3-6, 2001, in Leipzig covered aspects of viral hepatitis and its treatment in several sessions and gave latest results on treatment with interferon-alfa, lamivudine, and adefovir in
hepatitis B
as well as interferon-alfa, pegylated interferon-alfa, and ribavirin in hepatitis C and HCV-HIV co-infection respectively.
...
PMID:Therapy of chronic hepatitis B and C and treatment options in HCV-HIV co-infection--European Conference on Infectious Diseases and Tropical Medicine, EuCID 2001, 3-6 May 2001, Leipzig. 1143 99
Hepatocellular carcinoma (
HCC
or hepatoma) is the most common primary cancer of the liver. It is responsible for approximately one million deaths each year, mainly in underdeveloped and developing countries. The aetiological factors identified in the development of
HCC
included persistent infection by
hepatitis B
and hepatitis C viruses, and exposure to aflatoxins. Although immunization can protect individuals from being infected by the
hepatitis B
virus, the early detection of
HCC
in those who have been infected by the virus remains a challenge. Thus most HCCs present late and are not suitable for curative treatment. Hence there is a tremendous interest and urgency to identify novel
HCC
diagnostic marker(s) for early detection, and tumour specific disease associated proteins as potential therapeutic targets in the treatment of
HCC
. Screening for these
HCC
proteins has been facilitated by proteomics, a key technology in the global analysis of protein expression and understanding gene function. Present and earlier proteome analyses of
HCC
have used predominantly experimental in vitro systems. The protein expression profiles of several hepatoma cell lines such as HepG2, Huh7, SK-Hep1, and Hep3B have been compared with normal liver, and nontransformed cell lines (Chang and WRL-68), while a comprehensive proteome analysis to create a protein database was carried out for the cell line
HCC
-M. In the future, proteome analyses utilizing tumour tissues, which reflect the pathological state of
HCC
more closely, will be undertaken. This work will complement the gene expression studies of
HCC
which are already underway. Efforts have also been directed at the proteome analysis of hepatic stellate cells, as these cells play an important role in liver fibrosis. Since liver fibrosis is reversible but not cirrhosis, it is of considerable importance to identify therapeutic targets that can slow its progression.
...
PMID:Hepatocellular carcinoma: from bedside to proteomics. 1172 36
We report a patient with combined hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) growing into the common bile duct (CBD) and showing obstructive jaundice within 2 years of the onset of the disease. The patient was a 59-year-old Japanese man in whom, at the age of 57 years. a hepatic tumor was discovered by diagnostic imaging during follow-up of
hepatitis B
surface antigen (HBsAg)-positive liver cirrhosis. The tumor was diagnosed as
HCC
. Epirubicin was injected twice, intraarterially. The patient then received oral etoposide therapy for the next 14 months. The treatment was initially effective, but approximately 2 years after the hepatic tumor was discovered, local recurrence of the tumor and a tumor thrombus in the CBD were discovered. Although he was treated with percutaneous transhepatic biliary drainage (PTBD), to reduce obstructive jaundice, the jaundice was irreversible and he died of severe hepatic failure. The autopsy findings confirmed that the hepatic tumor was
HCC
-CC, in which the
HCC
and CC components expressed alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9), respectively, which accurately reflected the disease process. The underlying mechanism of the growth of
HCC
-CC into the CBD may differ from the underlying mechanism of the development of icteric-type
HCC
.
...
PMID:Combined hepatocellular carcinoma and cholangiocarcinoma growing into the common bile duct. 1177 13
To investigate the surgical results of hepatectomy for hepatocellular carcinoma in relation to hepatitis virus status in Taiwan, 252 patients (196 men and 56 women; March 1992 to August 1998) were reviewed. The patients were divided into four groups: 30 patients (11.9%) seronegative for both
hepatitis B
surface antigen (HBsAg) and antihepatitis C antibody (HCVAb) (N-
HCC
group); 133 patients (52.8%) seropositive for HBsAg and seronegative for HCVAb (B-
HCC
group); 66 patients (26.2%) seronegative for HBsAg and seropositive for HCVAb (C-
HCC
group); and 23 patients (9.1%) seropositive for both HBsAg and HCVAb (BC-
HCC
group). Patients in group C-
HCC
were older (p = 0.001) and had a higher incidence of diabetes mellitus (p = 0.004). Also, they had a higher indocyanine green retention rate at 15 minutes (p = 0.021), longer international normalization ratio for the prothrombin time (p = 0.049), and smaller tumor (p = 0.006). Postoperative complications and hospital mortality were significantly higher in patients in the C-
HCC
and BC-
HCC
groups (p = 0.046, 0.021). All patients were followed 12 to 76 months after hepatectomy (mean 23.5 +/- 16.3 months). The 1-, 3-, and 5-year overall cumulative survival rates of the 252 patients in this series were 80%, 54.3%, and 34.2%, respectively. The cumulative intrahepatic recurrence rates were 46.5%, 64.9%, and 72.9% at 1, 3, and 5 years, respectively. The mean disease-free survival time was longest in group C-
HCC
and shortest in group BC-
HCC
(p = 0.020). The overall survival time and cumulative survival rates in the four groups were not significantly different (p = 0.146).
...
PMID:Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan. 1205 31
Hepatitis B
virus (HBV) genotype C is predominant in Japan. However, many HBV subtypes are involved in each genotype, and the clinical manifestations in the patients associated with each subtype remain unknown. Therefore, we investigated the relationship between HBV subtype and clinical aspects of chronic HBV infection. The subtype of 237 patients with chronic HBV infection, including 74 asymptomatic carriers, was determined. The subtypes of 110 HBV carriers undergoing long-term follow-up management were determined twice to detect subtypic changes. The clinical features of the patients were also studied with regard to presence or absence of subtypic change. The subtypic distribution in the 237 HBV carriers was as follows: subtype adr, 161 (68%); subtype adw, 25 (11%); subtype adwr, 12 (5%); subtype ar, 24 (10%); subtype adyr, 4 (2%); and unclassified, 8 (3%). The proportion of asymptomatic carriers in patients with subtype adw was significantly higher than those in patients with subtype adr (56% vs. 28%, P < 0.05). In addition, the proportion of
HCC
in patients with subtype adwr was significantly higher than those in patients with subtype adr (25% vs. 6%, P < 0.05). The prevalence of subtype adr in 74 asymptomatic carriers tended to decrease with age (82% in carriers aged < or =35 years vs 43% in those aged > or =61 years, P < 0.05). The subtypic change and the course of chronic HBV infection had no significant correlation. These results suggest that HBV subtypes are associated with the clinical course of chronic HBV infection.
...
PMID:HBV subtype as a marker of the clinical course of chronic HBV infection in Japanese patients. 1221 Apr 5
To investigate the infection of HCV and the expression of HCV antigen (HCAg) in
HCC
, immunohistochemical protocol was performed on tumorous liver tissues from 40 patients with
HCC
to detect HCAg and
hepatitis B
virus surface antigen (HBsAg) simultaneously. The results showed that the positive rates for HCAg and HBsAg were 17.5% (7/40) and 70% (28/40) respectively. HBsAg and HCAg were simultaneously detected in six of 40 cases and only one case had HCAg positive alone in the liver tumorous tissue. The positive signals were localized in diffuse cytoplasm of hepatocytes and the positively stained cells were mainly distributed in local pattern. The results suggested that HCV infection did exist in some cases of
HCC
, so HCV might be a viral risk factor in addition to HBV in the genesis of
HCC
in China.
...
PMID:[Immunohistochemical detection of hepatitis C virus antigen from hepatocellular carcinoma]. 1221 37
Angiomyolipoma [AML] is a rare benign lipomatous tumour of the liver. It is typically echogenic on ultrasound, hypodense on computed tomography and hyperintense on magnetic resonance imaging. Its varied imaging appearance is due to the different proportion of the three cell types which make up the tumour. This is a case report of a hepatic AML mimicking hepatocellular carcinoma [
HCC
] with fatty change in a
hepatitis B
carrier. Diagnostic difficulty and implications on subsequent management are discussed in the context of an endemic region for
HCC
.
...
PMID:Hepatic angiomyolipoma mimicking hepatocellular carcinoma. 1237 26
China is an area of high endemicity for viral hepatitis, and the molecular epidemiological investigation of TT virus (TTV) infection is of interest. In the present study, we investigated the epidemiology, clinical significance and molecular characteristics of TTV infection in patients with chronic hepatitis B and C in Yanbian City, China. Serum samples obtained from 74 patients with
hepatitis B
and hepatitis C who visited Yanbian Hospital, located in northeast China, were analyzed in this study. The study group included 22 cases of chronic hepatitis B (B-CH), 17 cases of liver cirrhosis B (B-LC), 7 cases of hepatocellular carcinoma (B-HCC), 16 cases of chronic hepatitis C (C-CH), 11 cases of liver cirrhosis C (C-LC) and 1 case of hepatocellular carcinoma (C-HCC). Detection of TTV DNA was performed as described by Nishizawa et al. The second-round PCR products from 7 subjects were sequenced, followed by investigation of nucleotide homology and phylogenetic analysis. TTV DNA was present in 18.2, 5.9, 28.6, 6.3, 9.1 and 0% of the patients with B-CH, B-LC, B-
HCC
, C-CH, C-LC and C-
HCC
, respectively. The highest prevalence of TTV infection was seen in the groups aged 40-50 and over 60 years. There was no significant correlation between the presence of TTV DNA and the clinical parameters in patients with
hepatitis B
and C. The various isolates showed 97.9-100% with isolates reported previously from Japan and 98.4-100% with isolates reported previously from China. Nucleotide sequence analysis revealed that the Yanbian isolates could be classified in the same group as the Japan and China isolates. We concluded that chronic coinfection with TTV did not affect the serological features of chronic hepatitis B and C in China, as found in Tokyo, Japan.
...
PMID:TT virus infection does not affect the clinical profiles of patients with hepatitis B and C in Yanbian City, China. 1293 Oct 29
HBV infection is the single most common cause of cirrhosis globally although the prevalence rate is influenced by geographic region. The natural course of HBV infection and the clinical outcome is dependent on the interplay between host, virus, and environmental factors. Understanding the natural history of HBV infection is important in determining treatment strategies. OLT is the ultimate cure for patients with HBV-related liver failure or
HCC
. The use of HBIG and new antiviral agents has resulted in significant decrease in HBV re-infection rate and survival of patients transplanted for
hepatitis B
in recent years is comparable to that of patients transplanted for other liver disease.
...
PMID:Natural history of hepatitis B and outcomes after liver transplantation. 1450 24
Hepatocellular carcinoma caused by
hepatitis B
and hepatitis C are global scourges but are likely to peak in incidence in the next 2 decades and then decline. Universal vaccination has been effective in stemming the incidence of chronic hepatitis B and early-onset
HCC
in regions of high endemicity where implemented, but preventive measures in HCV are not yet available. After the attrition of older affected generations, the incidence of
HCC
will likely decline rapidly. While no vaccine is currently available for hepatitis C, cases are projected to peak and decline because of a marked reduction in transmission as a result of behavioral modification and safeguarding of blood supplies. Until these epidemiologic projections come to pass, management of hepatocellular carcinoma will continue to become a progressively more frequently encountered clinical challenge. Therapy for chronic hepatitis may ameliorate but will not eliminate the development of tumors. The demand for orthotopic liver transplantation will continue to climb, and palliative therapies for non-resectable cases will require studies aimed at optimization of benefit. LDLT may remain an option for high-risk patients affording tumor-free survival for some otherwise terminal patients.
...
PMID:Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. 1450 34
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>